With our clinical care, research and production facilities all on one campus, City of Hope has one of the most comprehensive CAR T programs worldwide. Our researchers and physicians are advancing CAR T cell therapy by applying our proprietary technology across a wide range of blood cancers and solid tumors. We are conducting over 70 CAR T and other immune effector cell trials and to-date, over 1,000 patients have participated in those trials or have been treated with Food and Drug Administration-approved CAR T cell therapies. Due to City of Hope’s longstanding expertise delivering CAR T therapy, most CAR T treatments currently administered at City of Hope are provided in an outpatient setting.
Additionally, several of our trials utilize allogeneic CAR T cells, the next generation of CAR T therapy. Unlike first-generation (autologous) CAR T cells, where T cells are collected from cancer patients and require a two to three week manufacturing period, allogeneic CAR T cells utilize cells from healthy donors, making them “off-the-shelf” in nature and easily manufactured in large batches for on-demand delivery to patients.*
Read below to learn about 3 clinical trials in recruitment that are assessing the safety and efficacy of different allogeneic CAR T therapies to treat large B cell lymphoma, multiple myeloma and renal cell carcinoma.
ALPHA 2 Study for Large B Cell Lymphoma
Title:
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Summary:
The purpose of the ALPHA-2 study is to assess the safety, efficacy, and cell kinetics of ALLO-501A in adults with relapsed or refractory large B-cell lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide and ALLO-647.
Principal Investigator:
Leslie L. Popplewell, M.D., Chief, Division of Lymphoma, and Associate Professor at City of Hope’s Toni Stephenson Lymphoma Center
UNIVERSAL Study for Multiple Myeloma
Title:
A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma
Summary:
The purpose of the single-arm, open-label, phase 1 UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide or ALLO-647 alone.
Principal Investigator:
Maung Myo Htut, M.D., Associate Professor, Division of Multiple Myeloma, Department of Hematology & Hematopoietic Cell Transplantation
TRAVERSE Study for Renal Cell Carcinoma
Title:
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Summary:
This is a Phase 1 dose escalation study following a 3+3 study design. The purpose of the TRAVERSE study is to assess the safety, efficacy, and cell kinetics of ALLO-316 in adults with advanced or metastatic clear cell renal cell carcinoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide and ALLO-647 to define a Phase 2 dose.
Principal Investigator:
Sumanta Kumar Pal, M.D., Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program
*City of Hope has partnered with Allogene Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer. Allogene launched CAR T Together™, a first-of-its-kind effort comprised of leading clinical trial investigators who represent the field of clinicians committed to supporting the development of “off-the-shelf” (allogeneic) chimeric antigen receptor (CAR) T products to make CAR T therapy scalable and more accessible to patients with certain cancers. For more information about CAR T Together, visit www.CARTTogether.com.
For all CAR T Inquiries (patient, physician, clinical trials) call 833-310-CART (2278) or visit CityofHope.org/research/find-a-clinical-trial for additional information about clinical trials at City of Hope.